POWER OF ATTORNEY TO PR	OSECUTE AP	PLICATIONS	BEFORE THE	USPTO
I hereby revoke all previous powers of attorne 87 CFR 3.73(b).	y given in the ap	plication identifie	d in the attached st	atement under
I hereby appoint:				
Practitioners associated with the Customer Number	er: 455	11		
OR	L			
Practitioner(s) named below (if more than ten pate	int practitioners are to	be named, then a c	ustomer number must be	used):
Name	Registration Number		Name	Registration Number
	1	8		
	8			
as attorney(s) or agent(s) to represent the undersigned be any and all patent applications assigned only to the under attached to this form in accordance with 37 GFR 3.73(b).	ersigned according to	es Palent and Trade the USPTO assigns	mark Office (USPTO) in tent records or assignme	connection with nt documents
Please change the correspondence address for the appli		altoched statemen	under 37 CFR 3.73(b) to	
The address associated with Customer Number	45511			
Firm or Individual Name	•			1
Address				
City	State	······································	Zip	
Country				
		Email		
Telephone		Guisi		
Assignes Name and Address:			200	
Janssen Pharmaceutica N.V. Turnhoutseweg 30				
Bearse, Belgium B-2340				:
A copy of this form, together with a statement filed in each application in which this form is u the practitionors appointed in this form if the a and must identify the application in which this	used. The stateme appointed practition	ent under 37 CFR oner is authorized	3.78(b) may be com	pleted by one of
SiG The individual whose signature and t	NATURE of Assigna	e of Record	on behalf of the assign	ıc
Signature March A. Apollo				
71007 01.0797			3-13	
Name Mary A. Appolling			Telephone 732	-524-374
	and 1.33. The information	on is required to obtain	or retain a benefit by the nu	blic which is to the fand
This collection of information is required by \$7 CFR 1.31, 1.32 by the USPTO to process) an application. Confidentially is got to complete, including gathering; preparing, and automiting the comments on the amount of time you require to complete this	remed by 35 U.S.C. 122 completed application for form end/or suggestion:	and 37 CFR 1.11 and my to the USPTO. Tire for reducing this bure	1.16 This collection is esting way vary depending upon the child be sent to the C	mated to take 3 minutes he individual case. Any hief Information Officer

U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1499, Alexandria, VA. 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

STATEMENT UNDER 37 CFR 3.73(b)				
Applicant/Patent Owner: _JANSSEN PHARMACEUTICA N.V.				
Application No./Patent No.: 10/510,220 Filed/Issue Date: 10/01/2004				
Entitled: SUBSTITUTED AMINO ISOXAZOLINE DERIVATIVES AND THEIR USE AS ANTI-DEPRESSANTS				
_IANSSEN PHARMACEUTICA N.V a 2CORPORATION	ment agency, etc.)			
states that it is: 1. It is assignee of the entire right, title, and interest; or				
an assignee of less than the entire right, title and interest (The extent (by percentage) of its ownership interest is%)				
in the patent application/patent identified above by virtue of either:				
Al An assignment from the inventor(s) of the patent application/patent identified above. The assignment wa in the United States Patent and Trademark Office at Reel, Frame, or for whithereof is attached.				
OR B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assign	nee as follows:			
From: INVENTOR #3 OF 4 To: JANSSEN PHARMACEUTICA N.V. The document was recorded in the United States Patent and Trademark Office at Reel 019183 , Frame _urbb, or for which a copy thereof is attached.				
2. From: INVENTORS# 1, #2 AND # 4 OF 4 To: JANSSEN-CILAG S.A.				
The document was recorded in the United States Patent and Trademark Office at				
Reel <u>019184</u> , Frame <u>೮೭೨೮೦</u> , or for which a copy thereof is attached.				
3. From: _JANSSEN-CILAG S.A. To: _JANSSEN PHARMACEUTICA N.V.				
The document was recorded in the United States Patent and Trademark Office at Reel _019184, Frame _0149, or for which a copy thereof is attached.				
Reel 019104 , Frame 0149 , or for which a copy thereor is attached.				
Additional documents in the chain of title are listed on a supplemental sheet.				
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owne assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.	r to the			
[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to A Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. Set 302.08]				
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.				
/S. Maurice Valla/ 4/22/07	7			
Signature Date	е			
S. MAURICE VALLA 215-568-3	100			
Printed or Typed Name Telephone	Number			
ATTORNEY FOR APPLICANT/REG. NO. 43,966				

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 monutes to concern the control of the confidential process. The confidential process are control of the confidential process. The confidential process are confidentially an advantage of the confidential process. The confidential process are confidentially as a confidential process. The confidential process are confidentially as a confidential process. The confidential process are confidentially as a confidential process. The confidential process are confidentially as a confidential process. The confidential process are confidentially as a confidential process. The confidential process are confidentially as a confidential process. The confidential process are confidentially as a confidential process. The confidential process are confidentially as a confidential process. The confidential process are confidentially as a confidential process. The confidential process are confidentially as a confidential process. The confidential process are confidentially as a confidential process. The confidential process are confidentially as a confidential process. The confidential process are confidentially as a confidential process. The confidential process are confidentially as a confidential process. The confidential process are confidentially as a confidential process. The confidential process are confidentially as a confidential process. The confidential process are confidentially as a confidential process are confidentially as a confidential process. The confidential process are confidentially as a confidential process are confidentially as a confidential process. The confidential process are confidentially as a confidential process. The confidential process are confidentially as a confidential process are confidentially as a confidential process.